drugset / Trial / NCT00203177

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

NCT00203177

Phase 3 Completed 254 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.

Timeline

Start
2001-10
Primary completion
2006-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rasagiline Small molecule 0.5 mg Oral
Subject Rasagiline Small molecule 1 mg Oral

Indications